WallStreetZenWallStreetZen

NASDAQ: KNSA
Kiniksa Pharmaceuticals International Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Kiniksa Pharmaceuticals International revenue was $677.56M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $202.1M, up 11.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, KNSA annual revenue was $677.6M, with 60.1% growth year-over-year.

KNSA past revenue growth

How has KNSA's revenue growth performed historically?

Company
60.09%
Industry
379.98%
Market
88.6%
KNSA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
KNSA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
KNSA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

KNSA revenue history

Current Revenue
$677.6M
Current Earnings
$59.0M
Current Profit Margin
8.7%

Be the first to know when KNSA announces revenue.

KNSA Revenue History By Year

KNSA Yearly RevenueKNSA RevenueKNSA ChangeKNSA Revenue Growth
2025-12-31$677.56M$254.33M+60.09%
2024-12-31$423.24M$152.98M+56.60%
2023-12-31$270.26M$50.08M+22.74%
2022-12-31$220.18M$181.64M+471.24%
2021-12-31$38.54MN/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A

1 of 1

Kiniksa Pharmaceuticals International Revenue FAQ

What was KNSA's revenue last quarter?

On Invalid Date, Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported Q4 2025 revenue of $202.13 million up 64.95% year over year. In the same quarter last year, Kiniksa Pharmaceuticals International's revenue was $122.54 million.

What was Kiniksa Pharmaceuticals International's revenue in 2025?

Kiniksa Pharmaceuticals International's annual revenue for the twelve months ending Dec 31, 2025 was $677.56 million, a 60.09% increase year over year.

How much does Kiniksa Pharmaceuticals International make in a day?

Based on Kiniksa Pharmaceuticals International annual revenue for the past five years, KNSA makes an average of $893,033.42 per day.

What was Kiniksa Pharmaceuticals International's annual revenue growth in the past year?

As of Q1 2026, Kiniksa Pharmaceuticals International's revenue has grown 60.09% year over year. This is 319.89 percentage points lower than the US Biotechnology industry revenue growth rate of 379.98%. Kiniksa Pharmaceuticals International's revenue in the past year totaled $677.56 million.

How much does Kiniksa Pharmaceuticals International make in a year?

Kiniksa Pharmaceuticals International's revenue by year for the past five years is:
  • Kiniksa Pharmaceuticals International's revenue for the twelve months ending Dec 31, 2025 was $677.56 million, a 60.09% increase year over year.
  • Kiniksa Pharmaceuticals International's annual revenue for Dec 31, 2024 was $423.24 million, a 56.6% increase from 2023.
  • Kiniksa Pharmaceuticals International's annual revenue for 2023 was $270.26 million, a 22.74% increase from 2022.
  • Kiniksa Pharmaceuticals International's annual revenue for 2022 was $220.18 million, a 471.24% increase from 2021.
  • Kiniksa Pharmaceuticals International's annual revenue for 2021 was $38.54 million, a Infinity% increase from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.